Brian Godman

- Brian currently works with Governments, WHO, health authorities and their advisers as well as academics across countries and continents to enhance the quality and efficiency of prescribing. This includes both new and established medicines
- Co-founder of the Piperska Group in 2008 (Pan-European group of health authority/ health insurance company personnel and their advisers) and the MURIA (Medicines Utilisation Research in Africa) group in 2015
- Brian has published over 350 papers in peer-reviewed journals with multiple colleagues since 2008 - many listed in Pub Med
- Brian has no conflicts of interest to declare

Value-Based Alternative Payment Models

ISPOR Europe 2020 Professor Brian Godman













Key issues and their implications

- Expenditure on complex treatments including biological medicines will soon exceed 50% of total expenditure on medicines worldwide. Expenditure will continue rising with a considerable number of new medicines for oncology and orphan diseases in development with premium price expectations
- Concerns with available resources especially in Europe exacerbated by ageing populations
- However any initiatives introduced must be balanced against providing incentives to develop new medicines to meet continued unmet need
- This has resulted in:
 - Greater pro-activity among payers including new models to better manage the entry of new medicines
 - Alternative payment methods including MEAs and MCDAs as well as potentially fair pricing models and indication based pricing
 - Increasing use of low-cost multiple-sourced medicines and biosimilars where pertinent
 - Growth in disinvestment activities

Further details regarding potential models for disinvestment – also using patient level data – can be found in:

International Journal of Technology Assessment in Health Care An evidence-based framework for identifying technologies of no or low-added value (NLVT)

María Eugenia Esandi^{1,2}, Iñaki Gutiérrez-Ibarluzea^{3,4}, Nora Ibargoyen-Roteta³, and Brian Godman^{5,6,7}

International Journal of Technology Assessment in Health Care, 33-2 (2017), 579-287. © Cambridge University Press 2017 #c10.002/defacts1700000

HEALTH TECHNOLOGY PERFORMANCE Assessment: Real-World Evidence for Public Healthcare Sustainability

Augusto Afonso Guerro Júnior

cambridge.org/thc

SUS Collaborating Centre for Technology Azzessment and Excellence in Health, Universidade Federal de Minas Gerais

Department of Social Pharmacy, School of Pharmacy, Universidade Federal de Minas Gerais

Livia Lovato Pires de Lemas

SUS Collaborating Centre for Technology Assessment and Excellence in Health, Universidade Federal de Minas Gerais

Past-Graduation Program in Public Health, School of Medicine, Universidade Federal de Minas Gerais

the second se

lidenc:@gnail.com

Brian Godman

Aine Heaney

National Presarbing Service Medicinewise

Carlos Alberto Vaszallo Facultad de Ciencias Médicas, Universidad Nacional del Litoral

Björn Wettermark

Public Healthcare Services Committee, Department of Healthcare Development, Stockholm County Council

Department of Medicine Solva, Clinical Epidemiology/Clinical pharmacology, Katolinska Institutet and Katolinska University Hospital

Gatzka Bengurto-Arrate, litakt Gutterrez-Ibarluzea Osteba, Basque Office for ITA Ministry for Health, Basque Government This is the Swedish model to improve the managed entry of new medicines starting with horizon scanning and continuing post launch - worked well for hepatitis C and new medicines for ovarian cancer




FIGURE 1 The Swedish national process for managed introduction and follow-up of new medicines. Source: The Swedish Association of Local Authorities and Regions (2017a). Reproduced with permission from Sofe Averlind.

This was our published paper – available Open Access - and builds on the model we developed across Europe following the launch of DOACs




published: 05 October 2017 doi: 10.3389/tphar.2017.00674



The Early Awareness and Alert System in Sweden: History and Current Status

Irene Eriksson^{1,2}*, Björn Wettermark^{1,2}, Marie Persson³, Morgan Edström⁴, Brian Godman^{1,4,7}, Anna Lindhö⁴, Rickard E. Malmström^{2,4}, Helena Ramström³, Mia von Euler^{1,4,*} and Anna Bergkvist Christensen¹⁰

¹ Department of Healthcare Development, Slockholm Council, Slockholm, Sweden, ² Department of Medicine Solms, Karolinska Instituted, Solna, Seeden, ³ Healthcare Administration, Slockholm Councy Council, Slockholm, Seeden, ⁴ Department of Clinical Pharmacology, Councy Council of Oxforgölland, Linköping University Hospital, Linköping, Sweden, ⁴ Health Economics Unit, University of Linepool Management Scincol, Linepool, United Ningdom, ⁴ Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden, ⁷ Strathclyte Institute of Pharmacy and Economical Sciences, University of Strathclycle, Glasgow, Sizzitand, United Kingdom, ⁴ Department of Healthcare, Regional Head Office, Region Vietne Göteland, Gothenburg, Sweden, ⁴ Department of Clinical Science and Education, Södenjulthcard, Karolinska Instituted, Solna, Sweden, ¹⁰ Department of Medicines Management and Informatics, Regional Head Office, Region Stales, Maind, Solna, Sweden, ¹⁰ Department of Medicines Management and Informatics, Regional Head Office, Region Stales, Maind,



This was the model we developed across Europe to improve the managed entry of new medicines following concerns with the DOACs

It is based on three pillars starting prelaunch and ending post-launch These models to improve the managed entry of new medicines have worked well for new medicines for hepatitis C and ovarian cancer in Sweden

European Journal of Clinical Pharmacology (2018) 74:971–978 https://doi.org/10.1007/s00228-018-2456-y

PHARMACOEPIDEMIOLOGY AND PRESCRIPTION



Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden

P. Frisk^{1,2} • K. Aggefors¹ • T. Cars³ • N. Feltelius⁴ • S. A. Loov¹ • B. Wettermark^{1,5} • O. Weiland⁶

Targeted Oncology https://doi.org/10.1007/s11523-018-0604-z

ORIGINAL RESEARCH ARTICLE



Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study

Irene Eriksson^{1,2} · Björn Wettermark^{1,2} · Kjell Bergfeldt³

Managed entry schemes are growing across Europe/ wider to enhance access to new medicines but still concerns

- There has been a growth in managed entry agreements (also called risk sharing arrangements) across countries to enhance access to new premium priced medicines
- MEAs can be divided into:
 - Financial-based models, e.g. discounts, rebates, price capping (typical approach)
 - Outcome-based models, e.g. reimbursed price/ funding maintained based on achieving agreed outcomes, e.g. lipid levels in patients with CVD or agreed viral load reductions in patients with hepatitis C; alternatively free goods or rebates if agreed outcome measures are not achieved
- However there are a number of issues/ concerns that need to be resolved going forward. These include:
 - confidential discounts (with financial-based MEAs), i.e. concerns with transparency between countries – not every country will gain optimal discounts. This has been one of the factors behind developing health authority consortia in Europe, e.g. Beneluxa and Valetta
 - lack of good patient-level databases in the public sector to monitor outcome-based schemes
 although changing e.g. SACT in England and CMOP in Scotland
 - yearly budget confines (although amortization models are being discussed more with the introduction of gene therapies - and this trend will continue)
 - o who will fund subsequent treatment failures unless robust agreements

The advantages and concerns with managed entry agreements were discussed in our recent paper including key personnel from across countries ...

PharmacoEconomics (2020) 38:1165–1185 https://doi.org/10.1007/s40273-020-00943-1

REVIEW ARTICLE



Integrative Review of Managed Entry Agreements: Chances and Limitations

Carolina Zampirolli Dias^{1,2} · Brian Godman^{3,4,5,6} · Ludmila Peres Gargano^{1,2} · Pâmela Santos Azevedo^{1,2} · Marina Morgado Garcia^{1,2} · Maurílio Souza Cazarim⁷ · Laís Lessa Neiva Pantuzza¹ · Nelio Gomes Ribeiro-Junior² · André Luiz Pereira⁸ · Marcus Carvalho Borin^{1,2} · Santos Azevedo^{1,2} · Sabella de Figueiredo Zuppo^{1,2} · Roberto Iunes⁹ · Tomas Pippo¹⁰ · Renata Curi Hauegen¹¹ · Carlos Vassalo¹² · Tracey-Lea Laba¹³ · Steven Simoens¹⁴ · Sergio Márquez¹⁵ · Carolina Gomez¹⁶ · Luka Voncina¹⁷ · Carlos Vassalo¹² · Gisbert W. Selke¹⁸ · Livio Garattini¹⁹ · Hye-Young Kwon^{20,21} · Jolanta Gulbinovic²² · Aneta Lipinska²³ · Maciej Pomorski²³ · Lindsay McClure²⁴ · Jurij Fürst²⁵ · Rosana Gambogi²⁶ · Carla Hernandez Ortiz²⁶ · Vânia Cristina Canuto Santos²⁷ · Denizar Vianna Araújo²⁷ · Vânia Eloisa Araujo^{1,28} · Francisco de Assis Acurcio^{1,2} · Juliana Alvares-Teodoro^{1,2} · Augusto Afonso Guerra-Junior^{1,2}

... which built on our earlier papers regarding MEAs among Central and Eastern European countries and wider

PharmacoEconomics (2017) 35:1271-1285 DOI 10.1007/s40273-017-0559-4



ORIGINAL RESEARCH ARTICLE

The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications

Alessandra Ferrario¹ · Diāna Arāja² · Tomasz Bochenek³ · Tarik Čatić⁴ · Dávid Dankó⁵ · Maria Dimitrova⁶ · Jurij Fürst⁷ · Ieva Greičiūtė-Kuprijanov⁸ · Iris Hoxha⁹ · Arianit Jakupi¹⁰ · Erki Laidmäe¹¹ · Olga Löblová¹² · Ileana Mardare¹³ · Vanda Markovic-Pekovic^{14,15} · Dmitry Meshkov¹⁶ · Tanja Novakovic¹⁷ · Guenka Petrova¹⁸ · Maciej Pomorski¹⁹ · Dominik Tomek²⁰ · Luka Voncina²¹ · Alan Haycox²² · Panos Kanavos¹ · Patricia Vella Bonanno²³ · Brian Godman^{22,23,24} ... which built on our earlier papers regarding MEAs among Central and Eastern European countries and wider (continued)

Adamski et al. BMC Health Services Research 2010, 10:153 http://www.biomedcentral.com/1472-6963/10/153

BMC Health Services Research

CORRESPONDENCE

Open Access

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

Jakub Adamski^{*1}, Brian Godman^{*2,3,4}, Gabriella Ofierska-Sujkowska⁵, Bogusława Osińska⁵, Harald Herholz⁶, Kamila Wendykowska⁷, Ott Laius⁸, Saira Jan⁹, Catherine Sermet¹⁰, Corrine Zara¹¹, Marija Kalaba¹², Roland Gustafsson¹³, Kristina Garuolienè¹⁴, Alan Haycox⁴, Silvio Garattini³ and Lars L Gustafsson² Good databases and all oncologists working together in Catalonia in Spain enabled the successful introduction of an outcome based MEA for gefitinib





Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFRmutation positive non-small-cell lung cancer

Ana Clopes, Montse Gasol, Rosana Cajal, Luis Segú, Ricard Crespo, Ramón Mora, Susana Simon, Luis A Cordero, Candela Calle, Antoni Gilabert & Josep R Germà

We will see the growth in outcome based schemes in countries including the UK with improved collection of patient level data

- NICE has instigated 256 commercial in confidence agreements by October 2020 to enhance funding for new premium-priced medicines (https://www.nice.org.uk/about/what-we-do/patient-access-schemes-liaison-unit). Typically easier and quicker to apply a confidential discount
- However, NICE has also instigated new arrangements for the cancer drugs fund (CDF) which requires pharmaceutical companies applying to the CDF for funding for their new cancer medicine to provide additional data
- These include submitting an MEA as part of the justification incorporating details of potential data collection via the Systemic Anti-Cancer Therapy (SACT) Data (mandated dataset as part of the Health and Social Care Information Standards in England) to address issues of uncertainty – especially with immature data https://www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop.pdf
- NHS Scotland has also instigated the CMOP programme in cancer to address issues of routine data collection during outpatients to improve knowledge

Details of the England SACT database can be found in the recent paper of Bright et al (2020)



International Journal of Epidemiology, 2020, 15–15 doi: 10.1093/ije/dyz137 Advance Access Publication Date: 24 July 2019 Data Resource Profile



Data Resource Profile

Data Resource Profile: The Systemic Anti-Cancer Therapy (SACT) dataset

Chloe J Bright,¹* Sarah Lawton,¹ Stephen Benson,¹ Martine Bomb,¹ David Dodwell,² Katherine E Henson,¹ Sean McPhail,¹ Louise Miller,¹ Jem Rashbass,¹ Alice Turnbull¹ and Rebecca Smittenaar¹

¹National Cancer Registration and Analysis Service, Public Health England, London, UK and ²Nuffield Department of Population Health, University of Oxford, Oxford, UK

*Corresponding author. National Cancer Registration and Analysis Service, Public Health England, 2 Rivergate, Temple Quay, Bristol BS1 6EH, UK. E-mail: chloe.bright@phe.gov.uk

The CMOP programme was developed in Scotland to improve future care of oncology patients with better outcome information

- In 2017, the Scottish Government announced it was investing GB£300,000 in a programme to investigate whether medicines are as effective in the 'real world' as they are in clinical trials
- The Cancer Medicines Outcome Programme (CMOP) is a collaboration between NHS Greater Glasgow and Clyde and the University of Strathclyde (<u>https://cancerchallengescotland.com/sites/default/files/documents/event_item/PR_OMsPREMs_Info_Session_190417/cic_info_session_190417_marion_bennie.pdf</u>)
- This involves developing, agreeing and implementing data sets for cancer to help better manage patients CMOP's vision is 'to develop a process which provides feedback to our cancer care clinicians on local outcomes. This real life data on the benefits, and side effects, of cancer medicines can then be used to identify supportive care needs as well as inform shared clinical decision-making between clinicians and patients'. As such will help inform future investment/ disinvestment decisions in cancer care
- A study in prostate cancer was the first published outcome of CMOP

A study using patient level data in Scotland to evaluate treatment outcomes in patients with prostate cancer is the first published output of the CMOP programme



ORIGINAL REPORT

Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland

Kelly Baillie¹ | Tanja Mueller² | Jiafeng Pan³ | Jennifer Laskey¹ | Marion Bennie^{2,4} | Christine Crearie¹ | Kimberley Kavanagh³ | Samantha Alvarez-Madrazo² | David Morrison⁵ | Julie Clarke¹ | Aileen Keel⁶ | David Cameron⁷ | Olivia Wu⁵ | Amanj Kurdi² | Robert J. Jones^{1,8} Key areas for the future especially with new oncology medicines often launched with limited clinical trial data are agreements over funding and data collection – this was an issue with olaratumab


Applied Health Economics and Health Policy (2020) 18:5–16 https://doi.org/10.1007/s40258-019-00527-x

CURRENT OPINION



Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab

Caridad Pontes^{1,2} · Corinne Zara¹ · Josep Torrent-Farnell^{1,2} · Merce Obach¹ · Cristina Nadal³ · Patricia Vella-Bonanno⁴ · Michael Ermisch⁵ · Steven Simoens⁶ · Renata Curi Hauegen⁷ · Jolanta Gulbinovic⁸ · Angela Timoney^{4,9} · Antony P. Martin¹⁰ · Tanja Mueller⁴ · Anna Nachtnebel¹¹ · Stephen Campbell^{12,13} . Gisbert Selke¹⁴ · Tomasz Bochenek¹⁵ · Celia C. Rothe¹⁵ · Ileana Mardare¹⁶ · Marion Bennie⁴ · Jurij Fürst¹⁷ . Rickard E. Malmstrom¹⁸ · Brian Godman^{4,10,19,20}



Pressure from the media in the Netherlands resulted in pressure on the Ministry of Health to ignore the advice of the Dutch reimbursement agency about funding enzyme replacement therapy for Fabrys' disease (up to €3.3 million incremental cost / QALY) and up to €15million for alglucosidase alfa to treat Pompe's disease

The payers in the Netherlands realised this situation could not continue for the sustainability of European healthcare systems – led to the development of MCDAs for new biological medicines for orphan diseases involving all key stakeholder groups (TVF) European payers together with Pharmaceutical Companies and patient groups are developing MCDAs including those for orphan diseases. One output to date is the Transparent Value Framework (TVF) as part of the MOCA process

Criterion	Lower Degree	Medium Degree	High Degree
Available Alternatives/ Unmet Need, including non-pharmaceutical treatment options	yes, new medicine does not address unmet need	yes, but major unmet need still remains	no alternatives except best supportive care - new drug addresses major unmet need
 (Relative) Effectiveness, Degree of Net Benefit (Clinical Improvement, QoL, etc. vs. side effects, societal impact, etc.) relative to alternatives, including no treatment. 	incremental	major	curative
Response Rate (based on best available clinically relevant criteria)	<30%	30-60%	>60%
Degree of Certainty (Documentation)	promising but not well-documented	plausible	unequivocal

Payers in Italy are also using an MCDA approach to determine the level of innovation for new medicines as part of their reimbursement discussions

Received: 20 May 2019 Revised: 4 September 2019 Accepted: 15 September 2019

DOI: 10.1111/bcp.14138

ORIGINAL ARTICLE



Using GRADE methodology to assess innovation of new medicinal products in Italy

Filomena Fortinguerra¹ Filowanni Tafuri¹ Francesco Trotta¹ Antonio Addis²

¹ Italian Medicines Agency (AIFA), Rome, Italy ² Department of Epidemiology, Lazio Regional Health Service, Rome, Italy

Aim: In April 2017 the Italian Medicine Agency (AIFA) developed new criteria to grant any new medicinal product with an innovative designation. The aim of this study is to describe this new model and how it works.

We are also seeing a growth in fair pricing models – enhanced by recent WHO deliberations (2020). However, this needs to be balanced against necessary incentives – acknowledged to some extent in the AIM (European payer body) approach



ACCESS TO MEDICINES AND HEALTH PRODUCTS

AIM PROPOSES TO ESTABLISH A EUROPEAN DRUG PRICING MODEL FOR FAIR AND TRANSPARENT PRICES FOR ACCESSIBLE PHARMACEUTICAL INNOVATIONS

WHO guideline on country pharmaceutical pricing policies

In conclusion

- We will continue to see the growth in alternative pricing models including MEAs and MCDAs to enable health authorities to fund new premium priced medicines/ use existing resources more wisely
- In addition, we will see a growth in health authority IT/ EHR systems to improve data collection especially in priority areas including cancer, e.g. SACT and CMOP in the UK. This will help Pharma Companies and health authorities promote optimal treatment approaches when multiple choices exist, e.g. different NOACs and anti-TNFs as well as potentially introduce different pricing by indication and outcome
- Concurrent with this will increasingly be a re-evaluation of the prices/ discounts/ rebates of existing patented medicines when the medicine used in the initial negotiations loses its patent and becomes available either as a low cost oral generic or biosimilar under value-based pricing approaches
- This will necessarily require Pharmaceutical Companies to provide additional data to support prices/ new formulations or delivery systems to enhance their value. The same will happen with ongoing discussions regarding fair pricing models

Public database studies such as these enhance our understanding of the relative place of different DOACs without head-to-head RCTs



British Journal of Clinical Pharmacology Br J Clin Pharmacol (2019) 85 422–431 422

ORIGINAL ARTICLE

Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland

Correspondence Tanja Mueller, The Farr Institute of Health Informatics Research, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK. Tel.: +44 (0)141 548 2367; E-mail: tanja.muller@strath.ac.uk

Received 27 April 2018; Revised 6 November 2018; Accepted 8 November 2018

Tanja Mueller¹, Samantha Alvarez-Madrazo¹, Chris Robertson^{2,3}, Olivia Wu⁴ and Marion Bennie^{1,5}

¹The Farr Institute of Health Informatics Research, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK, ²Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK, ³Health Protection Scotland, NHS National Services Scotland, Glasgow, UK, ⁴Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK, and ⁵Public Health and Intelligence Strategic Business Unit, NHS National Services Scotland, Edinburgh, UK Similarly for different subcutaneous biologic medicines for patients with RA with such studies growing to provide future robust guidance when multiple choices are available and no RCTs

Open access

Research

BMJ Open Discontinuation, persistence and adherence to subcutaneous biologics delivered via a homecare route to Scottish adults with rheumatic diseases: a retrospective study

> Samantha Alvarez-Madrazo,⁹^{1,2} Kimberley Kavanagh,³ Stefan Siebert,⁴ Yvonne Semple,^{5,6} Brian Godman,^{7,8} Alessandra Maciel Almeida,⁹ Francisco de Assis Acurcio,⁹ Marion Bennie^{1,10}

Thank You

Happy to answer questions!

Brian.Godman@ki.se; Brian.godman@strath.ac.uk; briangodman@outlook.com